Clinical trials: Type1 Diabetes
Diabetic Ketoacidosis, Type 1 Diabetes
Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management
Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management
- Conditions
- Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
- Trial name
- NCT04567225
- Testing
- Early Glargine, Late Glargine, IV insulin infusion
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- The Cleveland Clinic
Type 1 Diabetes
Web-Based Simulation Tool For Self-Management Support In Type 1 Diabetes Mellitus
This project focuses on embedding the participants' own diabetes data into state-of-the-art technology platforms to constitute a novel educational simulation interface for decision-support in Type 1 Diabetes (T1D) - the Web-based…
- Trial name
- WST (NCT04439903)
- Testing
- Web-based Simulation Tool
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Virginia
Parents
Reducing Hypoglycemia Fear in Parents of Young Children With Type 1 Diabetes
Pilot of a novel video-based telemedicine intervention to reduce fear of hypoglycemia in parents of young children with type 1 diabetes.
- Trial name
- REDCHiP (NCT03879642)
- Testing
- REDCHiP
- Volunteers
- 43 people
- Sponsor
- University of Kansas Medical Center
Type 1 Diabetes
Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study
Subjects will use the Omnipod Horizon™ System in Manual Mode in an outpatient setting for 14-days. Subjects will be trained to use the Manual Mode feature of the Omnipod Horizon™ System including how to use the bolus calculator…
- Trial name
- NCT04320069
- Testing
- Omnipod Horizon™ Automated Glucose Control System
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Insulet Corporation
Type 1 Diabetes Mellitus
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)
A multi-center, randomized, crossover trial consisting of three sequential 12-week periods, with the HCL feature used during one period, the PLGS feature used during one period and SAP therapy (control) during one period.
- Trial name
- AIDE T1D (NCT04016662)
- Testing
- Tandem t:slim X2 with HCL or PLGS
- Where
- 4 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Jaeb Center for Health Research
Type 1 Diabetes
Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers both insulin and glucagon can improved glycemic control vs. usual in the outpatient environment.
- Trial name
- NCT01762059
- Testing
- Bi-homonal Bionic Pancreas, Usual care
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes Mellitus With Hypoglycemia
DailyDose Smart Snack Study for T1D on MDI
This is a single-center, open-label, crossover trial with two arms and two periods (2x2) and one-week washout period. The study is designed to evaluate the efficacy of an AI-based bedtime smart snack intervention in reducing…
- Trial name
- NCT05967260
- Testing
- DailyDose Smart Snack app, Dexcom G6 CGM
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Oregon Health and Science University
Diabetes Mellitus, Type 1
Gan & Lee Insulin Glargine Target Type (1) Evaluating Research
Primary Objective: •To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity Secondary Objective: Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin…
- Trial name
- GLITTER1 (NCT03371082)
- Testing
- Gan & Lee Insulin Glargine Injection, Lantus®
- Where
- 85 sites in United States, Czechia and 4 more
- Volunteers
- 576 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Type 1 Diabetes Mellitus
Closed-Loop Insulin Delivery in Children Less Than 7 Years of Age
The investigators are conducting this study to find out whether a new device can control blood sugar levels in children who have Type 1 diabetes.
- Trial name
- NCT01421225
- Testing
- Closed-loop Insulin Pump therapy, Standard Insulin Pump Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Boston Children's Hospital
Type 1 Diabetes Mellitus
Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control
The incorporation of continuous glucose sensors (CGS) into management of type 1 diabetes in adolescence could improve treatment outcomes.
- Trial name
- CGM-Teens (NCT00945659)
- Testing
- Continuous Glucose Sensor, Standard Care, CGS + Behavior Therapy
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Nemours Children's Clinic
Type1 Diabetes Mellitus
Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes
The purpose of this study is to reduce the frequency of hypoglycemia and severe hypoglycemic events in subjects who use insulin pens to treat their Type 1 Diabetes Mellitus (T1DM).
- Trial name
- DSS (NCT03093636)
- Testing
- Continuous Glucose Monitor (CGM)+Decision Support System (DSS), Continuous Glucose Monitor (CGM) alone
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of Virginia
Type 1 Diabetes Mellitus
A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)
The goal of this study is to determine if Hylenex recombinant leads to changes in the insulin time-action profiles and glucose responses when preadministered in the setting of continuous subcutaneous insulin infusion (CSII)…
- Trial name
- HALO-117-406 (NCT03662334)
- Testing
- Rapid Acting insulin with pre-treatment of rHuPH20
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Halozyme Therapeutics
Type 1 Diabetes
Real-life Data From Diabetic Patients on Closed-loop Pumps
To evaluate, in real life, the effect of closed-loop devices on the improvement of glycemic control in diabetic patients managed in the endocrinology departments of secondary care hospitals.
- Trial name
- BLOOM (NCT05418699)
- Testing
- closed-loop insulin pump
- Where
- 5 sites in France
- Volunteers
- 410 people
- Sponsor
- Groupe Hospitalier de la Rochelle Ré Aunis
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes
This trial is conducted in Japan. The aim of this clinical trial is to investigate the safety (with emphasis on hypoglycaemia) after switching from long-acting insulin analogue or intermediate-acting insulin to insulin degludec…
- Trial name
- NCT00841087
- Testing
- insulin degludec, insulin detemir, insulin aspart
- Where
- 8 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)
This study was an extension of the NIH-sponsored At-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who developed clinical type 1 diabetes after the…
- Trial name
- NCT04270942
- Testing
- teplizumab 1 mg/mL
- Where
- 8 sites in United States
- Volunteers
- 6 people
- Sponsor
- Provention Bio, a Sanofi Company
Diabetes, Diabetes Mellitus, Type 1
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
This trial is conducted in Africa, Europe and North America. The purpose of the trial is to investigate the efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes.
- Trial name
- ADJUNCT TWO™ (NCT02098395)
- Testing
- liraglutide
- Where
- 120 sites in United States, Austria and 11 more
- Volunteers
- 835 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes
The purpose of this study is to find out if very tight blood glucose control from the onset of Type 1 Diabetes can preserve beta cell function.
- Trial name
- NCT00891995
- Testing
- Closed loop, Home glucose monitoring, Insulin pump
- Where
- 5 sites in United States
- Volunteers
- 71 people
- Sponsor
- Jaeb Center for Health Research
Recent Onset type1 Diabetes
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function
Objectives The objective of this clinical trial is to assess whether ladarixin treatment has an effect to preserve β-cell function and delay the progression of T1D in adolescent and adult patients.
- Trial name
- NCT04628481
- Testing
- Ladarixin
- Where
- 57 sites in United States, Belgium and 6 more
- Volunteers
- 289 people
- Sponsor
- Dompé Farmaceutici S.p.A
Type1 Diabetes
Neural-net Artificial Pancreas (NAP)
This study is intended to assess a Neural-net Artificial Pancreas (NAP) implementation of an established AP controller - the University of Virginia Model Predictive Control Algorithm (UMPC).
- Trial name
- NAP (NCT05876273)
- Testing
- Neural-net Artificial Pancreas, University of Virginia Model Predictive Control
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Virginia
Diabetes Mellitus, Type 1
Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2
DEFEND-2 is a Phase 3 confirmatory study for the Phase 3 DEFEND-1 study. The study objective is to find out if an 8-day series of otelixizumab infusions leads to greater improvement in insulin secretion as compared with placebo.
- Trial name
- DEFEND-2 (NCT01123083)
- Testing
- Otelixizumab
- Where
- Italy
- Volunteers
- 179 people
- Sponsor
- GlaxoSmithKline